Research programme: multiple sclerosis therapy - Merck Serono

Drug Profile

Research programme: multiple sclerosis therapy - Merck Serono

Alternative Names: AS-900004

Latest Information Update: 15 Mar 2011

Price : $50

At a glance

  • Originator Merck Serono
  • Class Proteins
  • Mechanism of Action Chemokine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 15 Mar 2011 Preclinical development is ongoing in Switzerland
  • 14 Apr 2009 Preclinical development is ongoing Switzerland
  • 08 Jan 2007 Serono is now called Merck Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top